EP4164645A4 - Composition antibactérienne combinée et procédé de thérapie antibactérienne - Google Patents

Composition antibactérienne combinée et procédé de thérapie antibactérienne

Info

Publication number
EP4164645A4
EP4164645A4 EP21825172.6A EP21825172A EP4164645A4 EP 4164645 A4 EP4164645 A4 EP 4164645A4 EP 21825172 A EP21825172 A EP 21825172A EP 4164645 A4 EP4164645 A4 EP 4164645A4
Authority
EP
European Patent Office
Prior art keywords
antibacterial
combination
therapy
composition
antibacterial composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21825172.6A
Other languages
German (de)
English (en)
Other versions
EP4164645A1 (fr
Inventor
Rajneesh Taneja
Pirthi Pal Singh
Veena Vithalapuram
Jagadeesh Nadigoti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Alliance for TB Drug Development Inc
Original Assignee
Global Alliance for TB Drug Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Alliance for TB Drug Development Inc filed Critical Global Alliance for TB Drug Development Inc
Publication of EP4164645A1 publication Critical patent/EP4164645A1/fr
Publication of EP4164645A4 publication Critical patent/EP4164645A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21825172.6A 2020-06-15 2021-06-14 Composition antibactérienne combinée et procédé de thérapie antibactérienne Pending EP4164645A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041025104 2020-06-15
PCT/US2021/037252 WO2021257466A1 (fr) 2020-06-15 2021-06-14 Composition antibactérienne combinée et procédé de thérapie antibactérienne

Publications (2)

Publication Number Publication Date
EP4164645A1 EP4164645A1 (fr) 2023-04-19
EP4164645A4 true EP4164645A4 (fr) 2024-07-10

Family

ID=79268322

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21825172.6A Pending EP4164645A4 (fr) 2020-06-15 2021-06-14 Composition antibactérienne combinée et procédé de thérapie antibactérienne

Country Status (2)

Country Link
EP (1) EP4164645A4 (fr)
WO (1) WO2021257466A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020998A1 (fr) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited Compositions pharmaceutiques a base de moxifloxacine et leurs procedes de preparation
US20110190199A1 (en) * 2008-09-03 2011-08-04 Pfizer Inc. Combination Therapy for Tuberculosis
WO2016120258A1 (fr) * 2015-01-27 2016-08-04 Janssen Pharmaceutica Nv Compositions dispersibles
US20180280401A1 (en) * 2015-10-14 2018-10-04 The Global Alliance For Tb Drug Development, Inc. Combination antibacterial composition and short-course antibacterial regimen
WO2021016012A1 (fr) * 2019-07-19 2021-01-28 The Global Alliance For Tb Drug Development, Inc. Compositions de prétomanide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116908C2 (uk) * 2013-08-09 2018-05-25 Ґлаксосмітклайн Інтеллекчуал Проперті (№ 2) Лімітед Сполуки трициклічного бензоксаборолу та їх застосування
JP2017533220A (ja) * 2014-11-03 2017-11-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 結核処置のための多剤療法
BR112019017901A2 (pt) * 2017-03-01 2020-05-12 Janssen Sciences Ireland Unlimited Company Terapia de combinação

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020998A1 (fr) * 2003-09-03 2005-03-10 Ranbaxy Laboratories Limited Compositions pharmaceutiques a base de moxifloxacine et leurs procedes de preparation
US20110190199A1 (en) * 2008-09-03 2011-08-04 Pfizer Inc. Combination Therapy for Tuberculosis
WO2016120258A1 (fr) * 2015-01-27 2016-08-04 Janssen Pharmaceutica Nv Compositions dispersibles
US20180280401A1 (en) * 2015-10-14 2018-10-04 The Global Alliance For Tb Drug Development, Inc. Combination antibacterial composition and short-course antibacterial regimen
WO2021016012A1 (fr) * 2019-07-19 2021-01-28 The Global Alliance For Tb Drug Development, Inc. Compositions de prétomanide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021257466A1 *

Also Published As

Publication number Publication date
WO2021257466A1 (fr) 2021-12-23
EP4164645A1 (fr) 2023-04-19

Similar Documents

Publication Publication Date Title
IL279748A (en) Preparation and method for treating pain
IL285886A (en) Preparations and methods for the treatment of laminopathy
GB202011871D0 (en) Composition and method
IL277315B (en) Method and preparations for treating the corona virus infection
IL285796A (en) Methods and preparations for the treatment of cancer
EP4181928A4 (fr) Compositions et procédés pour le traitement d'une inflammation pulmonaire
GB2593010B (en) Composition and Method
GB202100997D0 (en) Composition and method
GB202100998D0 (en) Composition and method
EP4164626A4 (fr) Composition antibactérienne polythérapeutique et méthode de thérapie antibactérienne
EP4164645A4 (fr) Composition antibactérienne combinée et procédé de thérapie antibactérienne
GB202102310D0 (en) Composition and method
GB202016644D0 (en) Composition and method
EP3946302A4 (fr) Procédés et compositions pour le traitement de la douleur
GB2598715B (en) Composition and method
EP4142687C0 (fr) Composition pour traiter et/ou prévenir la vestibulodynie
EP4175627A4 (fr) Composition et procédé de traitement d'infections
EP4069701A4 (fr) Composition et méthode de traitement du cancer
GB202113086D0 (en) Composition and method
GB202113085D0 (en) Composition and method
GB202218059D0 (en) Treatment composition
GB202109827D0 (en) Method and composition
GB202108601D0 (en) Composition and method
GB202105673D0 (en) Method and composition
GB202018825D0 (en) Composition and method

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031470000

Ipc: A61K0009160000

A4 Supplementary search report drawn up and despatched

Effective date: 20240607

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 17/02 20060101ALI20240603BHEP

Ipc: A61K 31/7036 20060101ALI20240603BHEP

Ipc: A61K 31/20 20060101ALI20240603BHEP

Ipc: A61K 9/20 20060101ALI20240603BHEP

Ipc: A61K 9/16 20060101AFI20240603BHEP